Bacterial infection poses life-threatening challenge to humanity and stimulates to the researchers for developing better diagnostic and therapeutic agents complying with existing theranostic techniques. Nuclear medicine technique helps to visualize hard-to-diagnose deep-seated bacterial infections using radionuclide-labeled tracer agents. Metronidazole is an antiprotozoal antibiotic that serves as a preeminent anaerobic chemotherapeutic agent. The aim of this study was to develop technetium-99m-labeled metronidazole radiotracer for the detection of deep-seated bacterial infections. Radiosynthesis of ^99mTc-metronidazole was carried by reacting reduced technetium-99m and metronidazole at neutral pH for 30 min. The stannous chloride dihydrate was used as the reducing agent. At optimum radiolabeling conditions, ~ 94% radiochemical was obtained. Quality control analysis was carried out with a chromatographic paper and instant thin-layer chromatographic analysis. The biodistribution study of radiochemical was performed using Escherichia coli bacterial infection-induced rat model. The scintigraphic study was performed using E. coli bacterial infection-induced rabbit model. The results showed promising accumulation at the site of infection and its rapid clearance from the body. The tracer showed target-to-non-target ratio 5.57 ± 0.04 at 1 h post-injection. The results showed that ^99mTc-MNZ has promising potential to accumulate at E. coli bacterial infection that can be used for E. coli infection imaging.

2006-01-01·Urology journal4区 · 医学

Ethylenedicysteine versus diethylenetriamine pentaacetic acid as the carrier of technetium Tc 99m in diuretic renography for patients with upper urinary tract obstruction.

4区 · 医学

ArticleOA

作者: Amir Mohammad Orafa ; Sepideh Hekmat ; Mansour Movahhed ; Mohammad Ali Zargar Shoshtari ; Hossein Shahrokh

INTRODUCTIONL,L-ethylenedicysteine (EC) is a new carrier of technetium Tc 99m (99mTc) with a lower affinity to plasma albumin in comparison with diethylenetriamine pentaacetic acid (DTPA). We compared 99mTc-EC scan with 99mTc-DTPA scan in diuretic renography for patients with obstructive uropathy.MATERIALS AND METHODSThirty-three patients with upper urinary tract obstruction were randomly selected and underwent diuretic renographies by 99mTc-EC and 99mTc-DTPA. The counts of radioisotope per pixel in the target (the kidney) and background tissues as well as the clearance half-life of these two radiopharmaceuticals were measured and compared.RESULTSMean counts of radioisotope per pixel in the target tissue was not different between 99mTc-EC and 99mTc-DTPA scans, but in the background tissue, it was less for 99mTc-EC (P = .003). Target-background ratio was higher for 99mTc-EC scan (3.80 +/- 2.11 versus 2.48 +/- 1.39; P < .001). Renal clearance half-life of radioisotope was shorter for 99mTc-EC scan than 99mTc-DTPA scan (58.15 +/- 15.17 minutes versus 78.65 +/- 19.99 minutes; P = .033). The results were similar for uremic patients (with a serum creatinine level > 2mg/dL).CONCLUSIONTarget-background ratio of radiopharmaceutical uptake rates in diuretic renography was a good indicator of the higher resolution of 99mTc-EC than 99mTc-DTPA scan. We also demonstrated the faster clearance of 99mTc-EC than 99mTc-DTPA. This results in less radiation that is especially useful in children. To our opinion, 99mTc-EC can better depict the kidneys in comparison with 99mTc-DTPA.

2002-04-01·Cancer Biotherapy and Radiopharmaceuticals4区 · 医学

Assessment of Antiangiogenic Effect Using^99mTc-EC-Endostatin

4区 · 医学

Article

作者: Kim, E. Edmund ; Kim, Kil-Dong ; Yu, Dong-Fang ; Abbruzzes, James ; Fogler, William E. ; Ozaki, Kaoru ; Roach, Jennifer S. ; Bryant, Jerry L. ; Yang, David J. ; Podoloff, Donald A. ; Azhdarinia, Ali ; Schechter, Naomi R. ; Kalimi, Saady K. ; Herbst, Roy ; Wu, Peng

PURPOSETumor vascular density may provide a prognostic indicator of metastatic potential or survival. The purpose of this study was to develop 99mTc-ethylenedicysteine-endostatin (99mTc-EC-endostatin) for the evaluation of anti-angiogenesis therapy.METHOD99mTc-EC-endostatin was prepared by conjugating ethylenedicysteine (EC) to endostatin, followed by adding pertechnetate and tin chloride. Radiochemical purity was > 95%. In vitro cell viability, affinity and TUNEL assays were performed. Tissue distribution and planar imaging of radiolabeled endostatin were determined in tumor-bearing rats. To assess anti-angiogenic treatment response, rats were treated with endostatin, paclitaxel and saline, followed by imaging with 99mTc-EC-endostatin. Tumor response to endostatin therapy in tumor-bearing animal models was assessed by correlating tumor uptake dose with microvessel density, VEGF, bFGF and IL-8 expression during endostatin therapy.RESULTSIn vitro cell viability and TUNEL assays indicated no marked difference between EC-endostatin and endostatin. Cellular uptake assay suggests that endostatin binds to endostatin receptor. Biodistribution of 99mTc-EC-endostatin in tumor-bearing rats showed increased tumor-to-tissue count density ratios as a function of time. Tumor uptake (%ID/g) of 99mTc-EC-endostatin was 0.2-0.5. Planar images confirmed that the tumors could be visualized clearly with 99mTc-EC-endostatin. The optimal time for imaging using radiolabeled endostatin was 2 hrs. 99mTc-EC-endostatin could assess treatment response. There was a correlation between tumor uptake and cellular targets expression.CONCLUSIONThe results indicate that it is feasible to use 99mTc-EC-endostatin to assess efficiency of anti-angiogenesis therapy.

100 项与 99mTc-EC-metronidazole 相关的药物交易

登录后查看更多信息